{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,4]],"date-time":"2022-04-04T11:02:14Z","timestamp":1649070134892},"reference-count":11,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2010,5,1]],"date-time":"2010-05-01T00:00:00Z","timestamp":1272672000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["La Presse M\u00e9dicale"],"published-print":{"date-parts":[[2010,5]]},"DOI":"10.1016\/j.lpm.2010.01.002","type":"journal-article","created":{"date-parts":[[2010,3,3]],"date-time":"2010-03-03T10:16:08Z","timestamp":1267611368000},"page":"527-529","source":"Crossref","is-referenced-by-count":0,"title":["Traitement enzymatique dans la maladie de Fabry\u00a0: ou quand le manque d\u2019un m\u00e9dicament rejoint le manque d\u2019\u00e9valuation th\u00e9rapeutique"],"prefix":"10.1016","volume":"39","author":[{"given":"Olivier","family":"Lidove","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriel","family":"Choukroun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soumeya","family":"Bekri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G\u00e9raldine","family":"Viot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michel","family":"Tsimaratos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominique","family":"Joly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.lpm.2010.01.002_bib1","unstructured":"IMS Health Incorporated. Orphan Drugs: Rarity No Guarantee of Access, 2009. Available on line at http:\/\/www.imshealth.com."},{"key":"10.1016\/j.lpm.2010.01.002_bib2","unstructured":"http:\/\/www.emea.europa.eu\/humandocs\/Humans\/EPAR\/replagal\/replagal.htm."},{"key":"10.1016\/j.lpm.2010.01.002_bib3","unstructured":"http:\/\/www.emea.europa.eu\/humandocs\/Humans\/EPAR\/fabrazyme\/fabrazyme.htm."},{"key":"10.1016\/j.lpm.2010.01.002_bib4","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1001\/jama.285.21.2743","article-title":"Enzyme replacement therapy in Fabry disease","volume":"285","author":"Schiffmann","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.lpm.2010.01.002_bib5","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJM200107053450102","article-title":"Safety and efficacy of recombinant human a-galactosidase A replacement therapy in Fabry's disease","volume":"345","author":"Eng","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2010.01.002_bib6","unstructured":"European Medicines Agency (EMEA). Questions and answers on the shortages of Cerezyme and Fabrazyme. 14-8-2009. Internet Communication."},{"key":"10.1016\/j.lpm.2010.01.002_bib7","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1097\/GIM.0b013e3181981d82","article-title":"Evaluation of a low dose, after a standard therapeutic dose, of agalsidase beta during enzyme replacement therapy in patients with Fabry disease","volume":"11","author":"Lubanda","year":"2009","journal-title":"Genet Med"},{"key":"10.1016\/j.lpm.2010.01.002_bib8","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.bcmd.2009.09.006","article-title":"Force majeure: therapeutic measures in response to restricted supply of imiglucerase (Cerezyme) for patients with Gaucher disease","volume":"44","author":"Hollak","year":"2010","journal-title":"Blood Cells Mol Dis"},{"key":"10.1016\/j.lpm.2010.01.002_bib9","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1681\/ASN.2006080816","article-title":"Sustained, long-term renal stabilization after 54\u00a0months of agalsidase beta therapy in patients with Fabry disease","volume":"18","author":"Germain","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.lpm.2010.01.002_bib10","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1681\/ASN.2008080870","article-title":"Agalsidase alfa and kidney dysfunction in Fabry disease","volume":"20","author":"West","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.lpm.2010.01.002_bib11","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/S0755-4982(06)74723-6","article-title":"Maladie de Fabry en 2006\u00a0: une \u00e9valuation th\u00e9rapeutique tr\u00e8s limit\u00e9e","volume":"35","author":"Lidove","year":"2006","journal-title":"Presse Med"}],"container-title":["La Presse M\u00e9dicale"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0755498210000692?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0755498210000692?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,12]],"date-time":"2018-12-12T21:53:25Z","timestamp":1544651605000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0755498210000692"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,5]]},"references-count":11,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2010,5]]}},"alternative-id":["S0755498210000692"],"URL":"https:\/\/doi.org\/10.1016\/j.lpm.2010.01.002","relation":{},"ISSN":["0755-4982"],"issn-type":[{"value":"0755-4982","type":"print"}],"subject":[],"published":{"date-parts":[[2010,5]]}}}